Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EvoPAR-PR05: saruparib plus physician's choice ARPI versus placebo plus physician's choice ARPI in mHSPC after docetaxel or 177Lu-PSMA
jRCT2031260625Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Nov 2026
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial in prostate cancer (PCa) comparing saruparib + physician's choice NHA with placebo + physician's choice NHA (2 arms). Primary endpoint: Radiographic progression-free survival. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
saruparib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on jRCT2031260625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260625.